

論文（主な英文論文のみ）

1. Masuko K, Okuda K, Meguro T, Murayama N, Mitsui T, Ohmori T, **Murata K**, Tsuda F, Okamoto H. Hepatitis C virus antibodies, viral RNA and genotypes in sera from patients on maintenance haemodialysis. *J Viral Hepatitis* 1994;1: 65-71.
2. Nakata S, Song P, Duc DD, Nguyen XQ, **Murata K**, Tsuda F, Okamoto H. Hepatitis C and B virus infections in populations at low or high risk in Ho Chi Minh and Hanoi, Vietnam. *J Gastroenterol Hepatol* 1994;9: 416-419.
3. Song P, Duc DD, Hien B, Nakata S, Chosa T, Watanabe J, Tsuda F, **Murata K**, Okamoto H. Markers of hepatitis C and B virus infections among blood donors in Ho Chi Minh City and Hanoi, Vietnam. *Clin Diagn Lab Immunol* 1994;1: 413-418.
4. Luengrojanakul P, Vareesangthip K, Chainuvati T, **Murata K**, Tsuda F, Tokita H, Okamoto H, Miyakawa Y, Mayumi M. Hepatitis C virus infection in patients with chronic liver disease or chronic renal failure and blood donors in Thailand. *J Med Virol* 1994;44: 287-292.
5. Kanazawa K, Yaoita H, Tsuda F, **Murata K**, Okamoto H. Association of prurigo with hepatitis C virus infection. *Arch Dermatol* 1995;131: 852-853.
6. **Murata K**, Oohashi Y, Takase K, Nakano T, Tameda Y. A case of hemobilia after percutaneous liver biopsy treated by transcatheter arterial embolization with Histoacryl. *Am J Gastroenterol* 1996;91: 160.
7. **Murata K**, Shiraki K, Takase K, Nakano T, Tameda Y. Long term follow-up for patients with liver cirrhosis after partial splenic embolization. *Hepatogastroenterology* 1996;43: 1212-1217.
8. **Murata K**, Shimizu A, Takase K, Nakano T, Tameda Y. Asymptomatic primary pulmonary hypertension associated with liver cirrhosis. *J Gastroenterol* 32: 102-104.
9. **Murata K**, Shimizu A, Takase K, Nakano T, Tameda Y. 1997. Liver cirrhosis with synchronous gas gangrene and spontaneous bacterial peritonitis due to E. coli. *J Gastroenterol* 1997;32: 264-267.
10. Yoshimura H, **Murata K**, Takase K, Nakano T, Tameda Y. A case of lipoma of the terminal ileum treated by endoscopic removal. *Gastrointest Endosc* 1997;46: 461-463.
11. **Murata K**, Sugimoto K, Okuda K, Shimizu A, Takase K, Nakano T, Tameda Y. Long-term effect of prophylactic endoscopic injection sclerotherapy on liver function. *Hepatogastroenterology* 1998;45: 1726-1730.
12. **Murata K**, Yoshimura H, Uemura S, Sugimoto K, Takase K, Nakano T. Disappearance of gastric antral vascular ectasia after percutaneous transhepatic obliteration. *Hepatogastroenterology* 1999;46: 185-188.
13. **Murata K**, Shiraki K, Kamei S, Takase K, Nakano T. Laparoscopic findings in an adult case

- of Alagille syndrome. *Endoscopy* 2000;32:536-538.
14. Lechmann M, **Murata K**, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus –like particles induce virus-specific humoral and cellular immune responses in mice. *Hepatology* 2001;34: 417-423.
  15. **Murata K**, Satoi J, Lechmann M, Manickan E, Zhang Z, Wedemeyer H, Rehermann B, Liang TJ. Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. *J Virol* 2001;75: 12121-12127.
  16. **Murata K**, Shiraki K, Sugimoto K, Takase K, Nakano T, Furusaka A, Tameda Y. Splenectomy enhances liver regeneration through tumor necrosis factor (TNF)-alpha following dimethylnitrosamine-induced cirrhotic rat model. *Hepatology* 2001;48: 1022-1027.
  17. **Murata K**, Shiraki K. Acute schistosoma mansoni infection in the liver. *J Hepatol* 2001;35: 147.
  18. **Murata K**, Shiraki K, Takase K, Nakano T, Tameda Y. Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C. *Hepatology* 2002;49: 1418-1419.
  19. Qiao M, **Murata K**, Davis AR, Jeong SH, Liang TJ. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. *Hepatology* 2003;37: 52-59.
  20. **Murata K**, Shiraki K, Kawakita T, Yamamoto N, Okano H, Nakamura M, Sakai T, Deguchi M, Ohmori S, Nakano T. Low-dose chemotherapy of cisplatin and 5-fluorouracil or doxorubicin via implanted infusion port for unresectable hepatocellular carcinoma. *Anticancer Res* 2003;23: 1719-1722.
  21. **Murata K**, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. *Proc Natl Acad Sci USA* 2003;100: 6753-6758.
  22. **Murata K**, Shiraki K, Kawakita T, Yamamoto N, Okano H, Takahisa S, Ohmori S, Masatoshi D, Atsuya S, Nakano T. Hepatocellular carcinoma presenting with obstructive jaundice: A clinicopathological study of eight cases. *Hepato-Gastroenterology* 2003;50: 2057-2060.
  23. Yamamoto N, **Murata K**, Fuke H, Inoue T, Yamanaka Y, Saitou Y, Ito K, Sugimoto K, Koyama M, Shiraki K, Nakano T. Macrocytic anemia during low-dose cisplatin and 5-fluorouracil through implanted infusion port for unresectable hepatobiliary malignancies. *Anticancer Res.* 2005;25:1243-1246.
  24. Yamamoto N, Ishikawa E, **Murata K**. Sclerosing encapsulating peritonitis. *J Gastroenterol Hepatol.* 2005;20:952.

25. **Murata K**, Yamamoto N, Kawakita T, Saito Y, Yamanaka Y, Sugimoto K, Shiraki K, Nakano T, Tameda Y. Up-regulation of IL-18 by interferon alpha/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C. *Hepato-Gastroenterology* 2005;52:547-551.
26. **Murata K**, Sugimoto K, Shiraki K, Nakano T. Relative predictive factors for hepatocellular carcinoma after HBeAg seroconversion in HBV infection. *World J Gastroenterol.* 2005;11(43):6848-6852.
27. Yamamoto N, **Murata K**, Nakano T. Remission of bronchial asthma after viral clearance in chronic hepatitis C. *World J Gastroenterol.* 2005;11(47):7545-7546.
28. **Murata K**, Sugimoto K, Hamada M, Nakano T. A novel mechanism for drug-induced liver failure: inhibition of histone acetylation by hydralazine derivatives. *J Hepatol* 2007;46:322-329.
29. **Murata K**, Inoue H, Kozuka Y. Gastric metastases from anaplastic pancreatic cancer. *Clin Gastroenterol Hepatol* 2007;5:e3.
30. **Murata K**, Moriyama M. Isoleucine, an essential amino acid, prevents liver metastases of colon cancer by antiangiogenesis. *Cancer Res* 2007;67:3263-3268.
31. Yoneda K, **Murata K**, Katayama K, Ishikawa E, Fuke H, Yamamoto N, Ito K, Shiraki K, Nomura S. Tubulointerstitial Nephritis Associated with IgG4-related Autoimmune Disease. *Am J Kid Dis* 2007;50:455-462.
32. **Murata K**, Ito K, Yoneda K, Shiraki K, Sakurai H, Ito M. Splenectomy improves liver function in patients with liver cirrhosis. *Hepato-Gastroenterology* 2008;55:1407-1411.
33. Yamamoto N, **Murata K**, Yoneda K, Fuke H, Yamaguchi Y, Ito K, Sugimoto K, Shiraki K, Yamanaka K, Mizutani H, Takei Y. Protective role of interleukin-18 against Fas-mediated liver injury. *Int J Mol Med* 2008;22:43-48.
34. **Murata K**, Sakamoto A. Impairment of clathrin-mediated endocytosis via cytoskeletal change by epithelial to fibroblastoid conversion in HepG2 cells: A possible mechanism of des- $\gamma$ -carboxy prothrombin production in hepatocellular carcinoma. *Int J Oncol* 2008;33:1149-1155.
35. Suzuki H, **Murata K**, Sakamoto A. Fulminant sepsis due to anaerobic bacterial infection in immuno-compromised state. *Leg Med (Tokyo)* 2009;11:237-240.
36. **Murata K**, Kase H, Kanemoto H. Primary malignant lymphoma of the ileum presenting as intussusception. *Intern Med* 2009;48:1559-1560.
37. **Murata K**, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des- $\gamma$ -carboxy prothrombin production in hepatocellular carcinoma. *Int J Oncol* 2009;35:1005-1014.
38. **Murata K**, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A. Hypoxia-induced

- des- $\gamma$ -carboxy prothrombin production in hepatocellular carcinoma. *Int J Oncol* 2010;36:161-170.
39. Ito K, Higami K, Masaki N, Sugiyama M, Mukaide M, Saito H, Aoki Y, Sato Y, Imamura M, **Murata K**, Nomura H, Hige S, Adachi H, Hino K, Yatsuhashi H, Orito E, Kani S, Tanaka Y, Mizokami M. The rs8099917 polymorphism, determined by a suitable genotyping method, is a better predictor for response to pegylated interferon- $\alpha$ /ribavirin therapy in Japanese patients than other SNPs associated with IL28B. *J Clin Microbiol* 2011;49:1853-1860.
40. Suzuki H, **Murata K**, Gotoh T, Kusano M, Okano H, Oyamada T, Yasuda Y, Imamura M, Kudo M, Mizokami M, Sakamoto A. Phenotype-dependent production of des- $\gamma$ -carboxy prothrombin in hepatocellular carcinoma. *J Gastroenterol* 2011;46:1219-1229.
41. Sugiyama M, Inui A, Shin-I T, Komatsu H, Mukaide M, Masaki N, **Murata K**, Ito K, Nakanishi M, Fujisawa T, Mizokami M. Easy-to-use phylogenetic analysis system for hepatitis B virus infection. *Hepatol Res* 2011;41:936-45.
42. Furui Y, Hoshi Y, **Murata K**, Ito K, Suzuki K, Uchida S, Satake M, Mizokami M, Tadokoro K. Prevalence of amino acid mutation in hepatitis C virus core region among Japanese volunteer blood donors. *J Med Virol* 2011;83:1924-1929.
43. Zeissig S, **Murata K**, Sweet L, Publicover J, Hu Z, Kaser A, Bosse E, Hussain MM, Balschun K, Rocken C, Arlt A, Gunther R, Hampe J, Schreiber S, Baron JL, Moody DB, Liang TJ, Blumberg RS. Hepatitis B virus-induced lipid alterations contribute to natural killer T cell-dependent protective immunity. *Nat Med* 2012;18:1060-1068.
44. Saito H, Ito K, Sugiyama M, Matsui T, Aoki Y, Imamura M, **Murata K**, Masaki N, Nomura H, Adachi H, Hige S, Enomoto N, Sakamoto N, Kurosaki M, Mizokami M, Watanabe S. Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients. *Hepatol Res* 2012;42:958-965.
45. Sugiyama M, Kimura T, Naito S, Mukaide M, Shinauchi T, Ueno M, Ito K, **Murata K**, Mizokami M. Development of specific and quantitative real-time detection PCR and immunoassays for  $\lambda$ 3-interferon. *Hepatol Res* 2012;42:1089-1099.
46. Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, **Murata K**, Masaki N, Tanaka Y, Hige S, Izumi N, Kurosaki M, Nishiguchi S, Sakamoto M, Kage M, Narimatsu H, Mizokami M. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. *Hepatology* 2012;56:1448-1456.
47. **Murata K**, Sugiyama M, Kimura T, Yoshio S, Kanto T, Kirikae I, Saito H, Aoki Y, Hiramane S, Matsui T, Ito K, Korenaga M, Imamura M, Masaki N, Mizokami M. Ex vivo

- induction of IFN- $\lambda$ 3 by a TLR7 agonist determines response to Peg-IFN/RBV therapy in chronic hepatitis C patients. *J Gastroenterol* 2014;49:126-137.
48. Takeda T, **Murata K**, Chatani N, Aoki Y, Yada T, Aoki Y, Koizuka H, Korenaga M, Imamura M, Kanto T, Masaki N, Ishida T, Watanabe S, Mizokami M, Uemura N. Scirrhous colonic metastasis from lobular carcinoma of breast. *Clin J Gastroenterol* 2013;6:291-294.
  49. Ito K, Yotsuyanagi H, Yatsushashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Tanaka Y, Sugiyama M, **Murata K**, Masaki N, Mizokami M, and the Japanese AHB Study Group. Risk factors for long-term persistence of serum hepatitis B surface antigen following acute hepatitis B virus infection in Japanese adults. *Hepatology* 2014;59:89-97.
  50. Nishida N, Sawai H, Kashiwase K, Minami M, Sugiyama M, Seto WK, Yuen MF, Posuwan N, Poovorawan Y, Ahn SH, Han KH, Matsuura K, Tanaka Y, Kurosaki M, Asahina Y, Izumi N, Kang JH, Hige S, Ide T, Yamamoto K, Sakaida I, Murawaki Y, Itoh Y, Tamori A, Orito E, Hiasa Y, Honda M, Kaneko S, Mita E, Suzuki K, Hino K, Tanaka E, Mochida S, Watanabe M, Eguchi Y, Masaki N, **Murata K**, Korenaga M, Mawatari Y, Ohashi J, Kawashima M, Tokunaga K, Mizokami M. New susceptibility and resistance HLA-DP alleles to HBV-related diseases identified by a trans-ethnic association study in Asia. *PLoS ONE* 2014;9:e86449.
  51. Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamura M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, **Murata K**, Ito K, Mizokami M. Pretreatment prediction of the outcome of response-guided peginterferon-a and ribavirin therapy for chronic hepatitis C. *J Gastroenterol Hepatol* 2014;29:1996-2005.
  52. Mukaide M, Sugiyama M, Korenaga M, **Murata K**, Kanto T, Masaki N, Mizokami M. High-throughput and sensitive next-generation droplet digital PCR assay for the quantitation of the hepatitis C virus mutation at core amino acid 70. *J Virol Methods* 2014;207:169-177.
  53. Aoki Y, Sugiyama M, **Murata K**, Yoshio S, Kurosaki M, Hashimoto S, Yatsushashi H, Nomura H, Kang JH, Takeda T, Naito S, Kimura T, Yamagiwa Y, Korenaga M, Masaki N, Izumi N, Kage M, Mizokami M, Kanto T. Association of serum IFN- $\lambda$ 3 with inflammatory and fibrosis markers in patients with chronic hepatitis C virus infection. *J Gastroenterol* 2015;50:894-902.
  54. Hiramine S, Sugiyama M, Furusho N, Uto H, Ido A, Tsubouchi H, Watanabe H, Ueno Y, Korenaga M, **Murata K**, Masaki N, Hayashi J, Thomas DL, Mizokami M. A thymine-adenine dinucleotide repeat polymorphism near IL28B is associated with spontaneous clearance of hepatitis C virus. *J Gastroenterol* 2015;50:1069-1077.
  55. Masaki N, Yamagiwa Y, Shimbo T, **Murata K**, Korenaga M, Kanto T, Mizokami M, and the

- prefectural members to the Japanese interferon Database. Regional disparities in interferon therapy for chronic hepatitis C in Japan: a nationwide retrospective cohort study. *BMC Public Health* 2015;15:566-576.
56. Ito K, Yotsuyanagi H, Sugiyama M, Yatsushashi H, Karino Y, Takikawa Y, Saito T, Arase Y, Imazeki F, Kurosaki M, Umemura T, Ichida T, Toyoda H, Yoneda M, Tanaka Y, Mita E, Yamamoto K, Michitaka K, Maeshiro T, Tanuma J, Korenaga M, **Murata K**, Masaki N, Koike K, Mizokami M, Japanese AHB and CHB Study Group. Geographic distribution and characteristics of genotype A hepatitis B virus infection in acute and chronic hepatitis B patients in Japan. *J Gastroenterol Hepatol* 2016;31:180-189.
  57. Yanase M, **Murata K**, Mikami S, Nozaki Y, Masaki N, Mizokami M. Hepatitis B virus vaccination-related seroprevalence among health-care personnel in a Japanese tertiary medical center. *Hepatol Res* 2016;46:1330-1337.
  58. Yamagiwa Y, Asano M, Kawasaki Y, Korenaga M, **Murata K**, Kanto T, Mizokami M, Masaki N. Pretreatment serum levels of interferon-gamma-inducible protein-10 are associated with virologic response to telaprevir-based therapy. *Cytokine* 2016;88:29-36.
  59. **Murata K**, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura IY, Dohi T, Shuno Y, Yano H, Mizokami M. Induction of IFN- $\lambda$ 3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for hepatitis B virus infection. *Gut* 2018;67:362-371. 10.1136/gutjnl-2016-312653
  60. Kawashima M, Hitomi Y, Aiba Y, Nishida N, Kojima K, Kawai Y, Nakamura H, Tanaka A, Zeniya M, Hashimoto E, Ohira H, Yamamoto K, Abe M, Nakao K, Yamagiwa S, Kaneko S, Honda M, Umemura T, Ichida T, Seike M, Sakisaka S, Harada M, Yokosuka O, Ueno Y, Senju M, Kanda T, Shibata H, Himoto T, **Murata K**, Miyake Y, Ebinuma H, Tani ai M, Joshita S, Nikami T, Ota H, Kouno H, Kouno H, Nakamuta M, Fukushima N, Kohjima M, Komatsu T, Komeda T, Ohara Y, Muro T, Yamashita T, Yoshizawa K, Nakamura Y, Shimada M, Hirashima N, Sugi K, Ario K, Takesaki E, Naganuma A, Mano H, Yamashita H, Matsushita K, Yamauchi K, Makita F, Nishimura H, Furuta K, Takahashi N, Kikuchi M, Masaki N, Tanaka T, Tamura S, Mori A, Yagi S, Shirabe K, Komori A, Migita K, Ito M, Nagaoka S, Abiru S, Yatsushashi H, Yasunami M, Shimoda S, Harada K, Egawa H, Maehara Y, Uemoto S, Kokudo N, Takikawa H, Ishibashi H, Chayama K, Mizokami M, Nagasaki M, Tokunaga K, Nakamura M. Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population. *Hum Mol Genet* 2017;26:650-659.
  61. Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsushashi H, Nagaoka S, Okuse C, Kagawa T,

- Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, **Murata K**, Tanaka E. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. *J Gastroenterol* 2018;53:247-257. 10.1007/s00535-017-1360-z
62. **Murata K**, Saito A, Katagiri S, Ariizumi S, Nakano M, Yamamoto M. Association of des- $\gamma$ -carboxy prothrombin production and Sonazoid-enhanced ultrasound findings in hepatocellular carcinoma of different histologic grades. *J Med Ultrason* 2018;45:223-229. 10.1007/s10396-017-0816-3
63. Nishida N, Sugiyama M, Sawai H, Nishina S, Sakai A, Ohashi J, Khor SS, Kakisaka K, Tsuchiura T, Hino K, Sumazaki R, Takikawa Y, **Murata K**, Kanda T, Yokosuka O, Tokunaga K, Mizokami M. Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to a hepatitis B vaccine. *Hepatology* 2018 (*in press*) 10.1002/hep.29876
64. Sawai H, Nishida N, Khor SS, Honda M, Sugiyama M, Baba N, Yamada K, Sawada N, Tsugane S, Koike K, Kondo Y, Yatsuhashi H, Nagaoka S, Taketomi A, Fukai M, Kurosaki M, Izumi N, Kang JH, **Murata K**, Hino K, Nishina S, Matsumoto A, Tanaka E, Sakamoto N, Ogawa K, Yamamoto K, Tamori A, Yokosuka O, Kanda T, Sakaida I, Itoh Y, Eguchi Y, Oeda S, Mochida S, Yuen MF, Seto WK, Poovorawan Y, Posuwan N, Mizokami M, Tokunaga K. Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. *Sci Rep* 2018;8(1):7958. 10.1002/hep.29876
65. Inoue-Shinomiya E, Murakawa M, Asahina Y, **Murata K**, Mizokami M, Watanabe M. The association of serum IFN- $\lambda$ 3 levels with hepatocarcinogenesis in chronic hepatitis C patients treated with direct-acting antiviral agents. *Hepatol Res* 2019;49:500-511. doi: 10.1111/hepr.13307
66. Hitomi Y, Ueno K, Kawai Y, Nishida N, Kojima K, Kawashima M, Aiba Y, Nakamura H, Kouno H, Kouno H, Ohta H, Sugi K, Nikami T, Yamashita T, Katsushima S, Komeda T, Ario K, Naganuma A, Shimada M, Hirashima N, Yoshizawa K, Makita F, Furuta K, Kikuchi M, Naeshiro N, Takahashi H, Mano Y, Yamashita H, Matsushita K, Tsunematsu S, Yabuuchi I, Nishimura H, Shimada Y, Yamauchi K, Komatsu T, Sugimoto R, Sakai H, Mita E, Koda M, Nakamura Y, Kamitsukasa H, Sato T, Nakamura M, Masaki N, Takikawa H, Tanaka A, Ohira H, Zeniya M, Abe M, Kaneko S, Honda M, Arai K, Arinaga-Hino T, Hashimoto E, Tani M, Umemura T, Joshita S, Nakao K, Ichikawa T, Shibata H, Takaki A, Yamagiwa S, Seike M, Sakisaka S, Takeyama Y, Harada M, Senju M, Yokosuka O, Kanda T, Ueno Y, Ebinuma H, Himoto T, **Murata K**, Shimoda S, Nagaoka S, Abiru S, Komori A, Migita K, Ito M, Yatsuhashi H, Maehara Y, Uemoto S, Kokudo N, Nagasaki M, Tokunaga K, Nakamura M. POGlut1, the putative effector gene driven by rs2293370 in primary

biliary cholangitis susceptibility locus chromosome 3q13.33. *Sci Rep* 2019;9(1):102 doi: 10.1038/s41598-018-36490-1

67. **Murata K**, Kang JH, Nagashima S, Matsui T, Karino Y, Yamamoto Y, Atarashi T, Oohara M, Uebayashi M, Sakata H, Matsubayashi K, Takahashi K, Arai M, Mishiro S, Sugiyama M, Mizokami M, Okamoto H. IFN- $\lambda$ 3 as a host immune response in acute hepatitis E virus infection. *Cytokine* 2020;125:154816 doi: 10.1016/j.cyto.2019.154816
68. **Murata K**, Tsukuda S, Suizu F, Kimura A, Sugiyama M, Watashi K, Noguchi M, Mizokami M. Immunomodulatory mechanism of acyclic nucleoside phosphates in treatment of hepatitis B virus infection. *Hepatology* doi: 10.1002/hep.30956
69. Yamada N, Murayama A, Shiina M, Aly HH, Iwamoto M, Tsukuda S, Watashi K, Tanaka T, Moriishi K, Nishitsuji H, Sugiyama M, Mizokami M, Shimotohno K, Muramatsu M, **Murata K**, Kato T. Anti-viral effects of interferon- $\lambda$ 3 on hepatitis B virus infection in cell culture. *Hepatol Res* 2019;22:283-291. doi: 10.1111/hepr.13449